{"denoms":[{"counts":[{"groupId":"BG000","value":"370"},{"groupId":"BG001","value":"369"},{"groupId":"BG002","value":"739"}],"units":"Participants"}],"groups":[{"description":"Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nOral palonosetron\n\nDexamethasone","id":"BG000","title":"Oral Palonosteron Plus Dexamethasone"},{"description":"Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nI.V. palonosetron\n\nDexamethasone","id":"BG001","title":"I.V. Palonosetron Plus Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.41","value":"58.0"},{"groupId":"BG001","spread":"9.92","value":"57.7"},{"groupId":"BG002","spread":"9.66","value":"57.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"151"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"303"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"219"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"436"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"321"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"641"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"96"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}],"populationDescription":"Safety population ie patients receiving either oral or IV palonosetron plus dexamethasone"}